European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma

NEXT STORY
NeoTX Announces FDA Clearance of IND for Phase 2 Clinical Trial of Naptumomab Estafenatox (NAP), its lead Tumor Targeted Superantigen Candidate
PREV STORY
Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novan’s NITRICIL™ Technology Shows In Vitro Antiviral Effect Against SARS-CoV-2 in Human Airway Infection Model

author_avatar
NASDAQ Market News

Translate Bio Announces Second Quarter 2019 Financial Results and Provides Corporate Update

author_avatar
NASDAQ Market News

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

author_avatar
NASDAQ Market News